Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Characterization of CPDM's Patient Derived Models

  • lab equipment

  • CPDM supports the characterization of patient derived models using various genomic and molecular approaches. Our standard approaches include:

    • Targeted Cancer Panel (ModelSeq)
    • Lineage Marker Expression nanoString panel (ModelExpress)
    • Low Pass WGS (ModelLP)
    • WES, WGS, RNASeq
    • STR Fingerprinting
    • Histopathology
    • In vitro Cell Viability Assay with PDX/PDCL in our semi-automated IncuCyte S3 live cell imaging platform and Tecan D300e drug dispensing platform
    • In vivo Studies with PDX/PDCL

    Once characterization data is acquired, data will be uploaded to a private instance of cBioPortal for analysis and visualization.

    Please email models@dfci.harvard.edu to learn more about our model characterization services.